Investors

Investing in Transformative Health Solutions for Fibro-Inflammatory Diseases

Endometriosis - A Critical Women's Health Challenge

Endometriosis impacts 10% of reproductive-age women globally, causing chronic pain, infertility, and significant financial burdens. In the U.S. alone, the condition costs approximately $22 billion annually in healthcare expenses and lost productivity. The current therapeutics market, valued at $3.16 billion in 2022, is projected to grow to $4.42 billion by 2027, presenting a substantial opportunity for innovative, disease-modifying treatments like FMC2.

Unlocking Market - Potential with Disease-Modifying Therapies

The fibro-inflammatory disease market offers immense opportunities, with conditions like endometriosis driving high demand for innovative solutions. By developing first-in-class, disease-modifying treatments, we aim to capture a significant share of these expanding markets, delivering transformative outcomes for patients while unlocking economic value for investors.

Market Opportunity

Fibro-inflammatory diseases, which include conditions like chronic kidney disease, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis (NASH), and systemic sclerosis, represent a significant area of unmet medical need.

These diseases are characterized by chronic inflammation and tissue fibrosis, which can lead to organ dysfunction and progressive, irreversible damage. Current treatments are limited, often focusing only on symptom management rather than addressing the underlying fibrosis and inflammation. For many patients, this results in a progressive decline in quality of life and a lack of long-term disease-modifying therapies.

The market potential for fibro-inflammatory disease therapies is substantial and rapidly growing. With rising global incidence, particularly due to ageing populations and lifestyle factors, analysts project that the market for treatments addressing fibrosis and inflammation could exceed tens of billions of dollars in the coming decade. Innovative therapies targeting fibrosis pathways or immune cell modulation—particularly those with high specificity and low toxicity—are anticipated to capture significant market share as they fulfil this critical need for disease-modifying options.

Investment Highlights

FimmCyte develops the first non-hormonal, disease-modifying treatment for endometriosis, targeting hormonal-resistant forms and unresectable lesions with a highly specific proprietary antibody.

Its novel target is differentially overexpressed in all major endometriosis subtypes, showing strong ex-vivo efficacy and potential for long-term remission due to immune memory. Cost-efficient and patent-protected, FMC2 could replace invasive surgeries, benefiting both healthcare providers and patients.

Additionally, this approach has applications in other fibrotic diseases, offering broader therapeutic possibilities. The technology is fully patent-protected, securing its market position with a first-mover advantage.

Join us in our mission to bring chronic disease-transforming therapies to a global market

Do you have a project you’re interested in discussing with us?